Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Inventory (2023 - 2025)

Tg Therapeutics (TGTX) has 3 years of Inventory data on record, last reported at $125.6 million in Q4 2025.

  • For Q4 2025, Inventory rose 13.7% year-over-year to $125.6 million; the TTM value through Dec 2025 reached $125.6 million, up 13.7%, while the annual FY2025 figure was $125.6 million, 13.7% up from the prior year.
  • Inventory reached $125.6 million in Q4 2025 per TGTX's latest filing, down from $147.0 million in the prior quarter.
  • Across five years, Inventory topped out at $157.8 million in Q1 2025 and bottomed at $27.2 million in Q1 2023.
  • Average Inventory over 3 years is $89.2 million, with a median of $83.0 million recorded in 2024.
  • Peak YoY movement for Inventory: surged 185.51% in 2024, then rose 13.7% in 2025.
  • A 3-year view of Inventory shows it stood at $39.8 million in 2023, then surged by 177.37% to $110.5 million in 2024, then increased by 13.7% to $125.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $125.6 million in Q4 2025, $147.0 million in Q3 2025, and $155.2 million in Q2 2025.